{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:56:11Z","timestamp":1762005371320,"version":"build-2065373602"},"reference-count":77,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"unspecified","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical Research Council","award":["MR\/L011794"],"award-info":[{"award-number":["MR\/L011794"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,10,4]]},"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>70%\u201384% of individuals with antipsychotic treatment resistance show non-response from the first episode. Emerging cross-sectional evidence comparing cognitive profiles in treatment resistant schizophrenia to treatment-responsive schizophrenia has indicated that verbal memory and language functions may be more impaired in treatment resistance. We sought to confirm this finding by comparing cognitive performance between antipsychotic non-responders (NR) and responders (R) using a brief cognitive battery for schizophrenia, with a primary focus on verbal tasks compared against other measures of cognition.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Cross-sectional.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>This cross-sectional study recruited antipsychotic treatment R and antipsychotic NR across four UK sites. Cognitive performance was assessed using the Brief Assessment of Cognition in Schizophrenia (BACS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>One hundred and six participants aged 18\u201365 years with a diagnosis of schizophrenia or schizophreniform disorder were recruited according to their treatment response, with 52 NR and 54\u2009R cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>Composite and subscale scores of cognitive performance on the BACS. Group (R vs NR) differences in cognitive scores were investigated using univariable and multivariable linear regressions adjusted for age, gender and illness duration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Univariable regression models observed no significant differences between R and NR groups on any measure of the BACS, including verbal memory (\u00df=\u22121.99, 95%\u2009CI \u22126.63 to 2.66, p=0.398) and verbal fluency (\u00df=1.23, 95%\u2009CI \u22122.46 to 4.91, p=0.510). This pattern of findings was consistent in multivariable models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The lack of group difference in cognition in our sample is likely due to a lack of clinical distinction between our groups. Future investigations should aim to use machine learning methods using longitudinal first episode samples to identify responder subtypes within schizophrenia, and how cognitive factors may interact within this.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trail registration number<\/jats:title>\n                  <jats:p>REC: 15\/LO\/0038.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-054160","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T11:37:23Z","timestamp":1637840243000},"page":"e054160","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5424-8261","authenticated-orcid":false,"given":"Edward","family":"Millgate","sequence":"first","affiliation":[{"name":"Department of Psychosis Studies, King\u2019s College London Institute of Psychiatry Psychology and Neuroscience, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Kravariti","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, King\u2019s College London Institute of Psychiatry Psychology and Neuroscience, London, UK"},{"name":"NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Egerton","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, King\u2019s College London Institute of Psychiatry Psychology and Neuroscience, London, UK"},{"name":"NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver D","family":"Howes","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, King\u2019s College London Institute of Psychiatry Psychology and Neuroscience, London, UK"},{"name":"NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin M","family":"Murray","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, King\u2019s College London Institute of Psychiatry Psychology and Neuroscience, London, UK"},{"name":"NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Kassoumeri","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, King\u2019s College London Institute of Psychiatry Psychology and Neuroscience, London, UK"},{"name":"NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Donocik","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, King\u2019s College London Institute of Psychiatry Psychology and Neuroscience, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sh\u00f4n","family":"Lewis","sequence":"additional","affiliation":[{"name":"Division of Psychology and Mental Health, The University of Manchester, Manchester, UK"},{"name":"Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0220-4835","authenticated-orcid":false,"given":"Richard","family":"Drake","sequence":"additional","affiliation":[{"name":"Division of Psychology and Mental Health, The University of Manchester, Manchester, UK"},{"name":"Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Lawrie","sequence":"additional","affiliation":[{"name":"Psychiatry, The University of Edinburgh Division of Psychiatry, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Murphy","sequence":"additional","affiliation":[{"name":"Division of Psychology and Mental Health, The University of Manchester, Manchester, UK"},{"name":"Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Collier","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, King\u2019s College London Institute of Psychiatry Psychology and Neuroscience, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Lees","sequence":"additional","affiliation":[{"name":"Division of Psychology and Mental Health, The University of Manchester, Manchester, UK"},{"name":"Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Stockton-Powdrell","sequence":"additional","affiliation":[{"name":"Division of Psychology and Mental Health, The University of Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Walters","sequence":"additional","affiliation":[{"name":"MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bill","family":"Deakin","sequence":"additional","affiliation":[{"name":"Division of Psychology and Mental Health, The University of Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"MacCabe","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, King\u2019s College London Institute of Psychiatry Psychology and Neuroscience, London, UK"},{"name":"NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"key":"2025101813533871000_11.11.e054160.1","unstructured":"National Institute for Health and Care Excellence . National collaborating centre for mental health (UK. psychosis and schizophrenia in adults: treatment and management) 2014."},{"key":"2025101813533871000_11.11.e054160.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2007.04.001"},{"key":"2025101813533871000_11.11.e054160.3","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291717000435"},{"key":"2025101813533871000_11.11.e054160.4","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18com12123","article-title":"Clinical guidance on the identification and management of treatment-resistant schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"2025101813533871000_11.11.e054160.5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s40263-016-0358-z","article-title":"Correlates of clozapine use after a first episode of schizophrenia: results from a long-term prospective study","volume":"30","author":"\u00dc\u00e7ok","year":"2016","journal-title":"CNS Drugs"},{"key":"2025101813533871000_11.11.e054160.6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/JCP.0000000000000649","article-title":"Predictors of nonhospitalization and functional response in clozapine treatment: a nationwide, population-based cohort study","volume":"37","author":"K\u00f6hler-Forsberg","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"2025101813533871000_11.11.e054160.7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.psychres.2017.01.064","article-title":"The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study","volume":"250","author":"Yoshimura","year":"2017","journal-title":"Psychiatry Res"},{"key":"2025101813533871000_11.11.e054160.8","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1017\/S0033291721000246","article-title":"Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis","volume":"51","author":"Griffiths","year":"2021","journal-title":"Psychol Med"},{"key":"2025101813533871000_11.11.e054160.9","article-title":"Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics","volume":"9","author":"Lally","year":"2016","journal-title":"Pharmgenomics Pers Med"},{"key":"2025101813533871000_11.11.e054160.10","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1304-4"},{"key":"2025101813533871000_11.11.e054160.11","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291716002014"},{"key":"2025101813533871000_11.11.e054160.12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S2215-0366(15)00575-1","article-title":"Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study","volume":"3","author":"Wimberley","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"2025101813533871000_11.11.e054160.13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1017\/S0033291719002083","article-title":"Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies","volume":"51","author":"Smart","year":"2021","journal-title":"Psychol Med"},{"key":"2025101813533871000_11.11.e054160.14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1192\/bjp.2019.120","article-title":"Clinical indicators of treatment-resistant psychosis","volume":"216","author":"Legge","year":"2020","journal-title":"Br J Psychiatry"},{"key":"2025101813533871000_11.11.e054160.15","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00067"},{"key":"2025101813533871000_11.11.e054160.16","unstructured":"Smart S . Clinical and genetic predictors of treatment resistant psychosis (Doctoral dissertation, King\u2019s College London) 2020."},{"key":"2025101813533871000_11.11.e054160.17","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.4.1.43"},{"key":"2025101813533871000_11.11.e054160.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2014.06.034"},{"key":"2025101813533871000_11.11.e054160.19","doi-asserted-by":"publisher","DOI":"10.1037\/a0014708"},{"key":"2025101813533871000_11.11.e054160.20","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.108.055590"},{"key":"2025101813533871000_11.11.e054160.21","unstructured":"Snitz BE , MacDonald III AW , Carter CS . Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes."},{"key":"2025101813533871000_11.11.e054160.22","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1017\/S0033291717001490","article-title":"Meta-analysis of longitudinal studies of cognition in bipolar disorder: comparison with healthy controls and schizophrenia","volume":"47","author":"Bora","year":"2017","journal-title":"Psychol Med"},{"key":"2025101813533871000_11.11.e054160.23","doi-asserted-by":"crossref","unstructured":"Fagerlund B , Pantelis C , Jepsen JR . Differential effects of age at illness onset on verbal memory functions in antipsychotic-na\u00efve schizophrenia patients aged 12\u201343 years. Psychol Med 2020;11.","DOI":"10.1017\/S0033291720000409"},{"key":"2025101813533871000_11.11.e054160.24","unstructured":"Millgate E , Hide O , Lawrie S . Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: a systematic review & meta-analysis. [Manuscript submitted for publication]. Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London."},{"key":"2025101813533871000_11.11.e054160.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2003.09.011"},{"key":"2025101813533871000_11.11.e054160.26","first-page":"24","article-title":"Executive function in schizophrenia","volume":"4","author":"Velligan","year":"1999","journal-title":"Semin Clin Neuropsychiatry"},{"key":"2025101813533871000_11.11.e054160.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2004.06.008"},{"key":"2025101813533871000_11.11.e054160.28","doi-asserted-by":"publisher","DOI":"10.1037\/0021-843X.114.4.599"},{"key":"2025101813533871000_11.11.e054160.29","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291708004558"},{"key":"2025101813533871000_11.11.e054160.30","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.4.526"},{"key":"2025101813533871000_11.11.e054160.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(03)00156-7"},{"key":"2025101813533871000_11.11.e054160.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(03)00125-7"},{"key":"2025101813533871000_11.11.e054160.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(02)00282-7"},{"key":"2025101813533871000_11.11.e054160.34","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/NMD.0b013e3181d61748","article-title":"Verbal fluency in schizophrenia: does cognitive performance reflect the same underlying mechanisms in patients and healthy controls?","volume":"198","author":"Ojeda","year":"2010","journal-title":"J Nerv Ment Dis"},{"key":"2025101813533871000_11.11.e054160.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.12.021"},{"key":"2025101813533871000_11.11.e054160.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.03.019"},{"key":"2025101813533871000_11.11.e054160.37","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-8-1"},{"key":"2025101813533871000_11.11.e054160.38","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association . Diagnostic and statistical manual of mental disorders (DSM-5\u00ae). American Psychiatric, 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2025101813533871000_11.11.e054160.39","doi-asserted-by":"crossref","unstructured":"Egerton A , Murphy A , Donocik J . Dopamine and glutamate in Antipsychotic-Responsive compared with Antipsychotic-Nonresponsive psychosis: a multicenter positron emission tomography and magnetic resonance spectroscopy study (strata). Schizophrenia Bulletin 2020.","DOI":"10.1093\/schbul\/sbaa128"},{"key":"2025101813533871000_11.11.e054160.40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7027.345"},{"key":"2025101813533871000_11.11.e054160.41","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.172.5.413"},{"key":"2025101813533871000_11.11.e054160.42","unstructured":"Guy W . ECDEU assessment manual for psychopharmacology. US department of health, education, and welfare, public health service, alcohol, drug abuse, and mental health administration, National Institute of mental health, psychopharmacology research branch, division of extramural research programs 1976."},{"key":"2025101813533871000_11.11.e054160.43","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"2025101813533871000_11.11.e054160.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(99)80239-9"},{"key":"2025101813533871000_11.11.e054160.45","unstructured":"Opler LA , Kay SR , Lindenmayer JP . Structured clinical interview: the positive and negative syndrome scale (SCI-PANSS). North Tonawanda, NY: Multi-Health Systems, 1999."},{"key":"2025101813533871000_11.11.e054160.46","doi-asserted-by":"publisher","DOI":"10.1016\/J.SCHRES.2008.03.024"},{"key":"2025101813533871000_11.11.e054160.47","unstructured":"StataCorp LL . Stata statistical software: release 15 College Station, TX, 2017. Available: www. stata. com\/features\/documentation\/ [Accessed 1 Mar 2018]."},{"key":"2025101813533871000_11.11.e054160.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.tics.2006.01.007"},{"key":"2025101813533871000_11.11.e054160.49","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13065su1.08"},{"key":"2025101813533871000_11.11.e054160.50","doi-asserted-by":"publisher","DOI":"10.1016\/0920-9964(92)90062-A"},{"key":"2025101813533871000_11.11.e054160.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2012.07.010"},{"key":"2025101813533871000_11.11.e054160.52","article-title":"Illness duration and neuropsychological impairments in schizophrenia","volume":"33","author":"Cuesta","year":"1998","journal-title":"Schizophr Res"},{"key":"2025101813533871000_11.11.e054160.53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000342345","article-title":"Negative symptoms and executive function in schizophrenia: does their relationship change with illness duration?","volume":"46","author":"Bagney","year":"2013","journal-title":"Psychopathology"},{"key":"2025101813533871000_11.11.e054160.54","unstructured":"Bulmer MG . Principles of statistics. Courier Corporation, 1979."},{"key":"2025101813533871000_11.11.e054160.55","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.167.2.202"},{"key":"2025101813533871000_11.11.e054160.56","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/oxfordjournals.schbul.a033421","article-title":"Nonresponding schizophrenia: differentiation by neurological soft signs and neuropsychological tests","volume":"25","author":"Smith","year":"1999","journal-title":"Schizophr Bull"},{"key":"2025101813533871000_11.11.e054160.57","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(01)00279-1"},{"key":"2025101813533871000_11.11.e054160.58","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.psychres.2013.06.042","article-title":"Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses","volume":"210","author":"de Bartolomeis","year":"2013","journal-title":"Psychiatry Res"},{"key":"2025101813533871000_11.11.e054160.59","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/13546805.2012.760917","article-title":"Clozapine and visuospatial processing in treatment-resistant schizophrenia","volume":"18","author":"Bourque","year":"2013","journal-title":"Cogn Neuropsychiatry"},{"key":"2025101813533871000_11.11.e054160.60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.psychres.2015.11.028","article-title":"Profiling cognitive impairment in treatment-resistant schizophrenia patients","volume":"235","author":"Frydecka","year":"2016","journal-title":"Psychiatry Res"},{"key":"2025101813533871000_11.11.e054160.61","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1017\/S0033291718002957","article-title":"Neuropsychological function at first episode in treatment-resistant psychosis: findings from the \u00c6SOP-10 study","volume":"49","author":"Kravariti","year":"2019","journal-title":"Psychol Med"},{"key":"2025101813533871000_11.11.e054160.62","doi-asserted-by":"crossref","DOI":"10.1016\/j.pscychresns.2020.111043","article-title":"Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: a comparison with matched treatment-responsive patients and healthy controls\u2730,\u2730\u2730,\u2605,\u2605\u2605","volume":"297","author":"Huang","year":"2020","journal-title":"Psychiatry Res Neuroimaging"},{"key":"2025101813533871000_11.11.e054160.63","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.psychres.2018.08.109","article-title":"Evaluation of a few discrete clinical markers may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: a study by ROC curve analysis and multivariate analyses","volume":"269","author":"Iasevoli","year":"2018","journal-title":"Psychiatry Res"},{"key":"2025101813533871000_11.11.e054160.64","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.npbr.2019.06.003","article-title":"Cognitive impairment in patients with treatment resistant schizophrenia: associations with DRD2, DRD3, HTR2A, BDNF and CYP2D6 genetic polymorphisms","volume":"33","author":"Sosin","year":"2019","journal-title":"Neurol Psych Brain Res"},{"key":"2025101813533871000_11.11.e054160.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2006.01.023"},{"key":"2025101813533871000_11.11.e054160.66","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/10826084.2018.1521430","article-title":"A systematic review of the symptom profile and course of methamphetamine-associated psychosis","volume":"54","author":"Voce","year":"2019","journal-title":"Subst Use Misuse"},{"key":"2025101813533871000_11.11.e054160.67","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.neuro.24.1.167"},{"key":"2025101813533871000_11.11.e054160.68","doi-asserted-by":"crossref","DOI":"10.1016\/j.bionps.2020.100015","article-title":"Prefrontal cortical alterations of glutamate and GABA neurotransmission in schizophrenia: insights for rational biomarker development","volume":"3","author":"Schoonover","year":"2020","journal-title":"Biomark Neuropsychiatry"},{"key":"2025101813533871000_11.11.e054160.69","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.biopsych.2020.06.027","article-title":"Associations between cognitive function and levels of glutamatergic metabolites and gamma-aminobutyric acid in antipsychotic-na\u00efve patients with schizophrenia or psychosis","volume":"89","author":"Bojesen","year":"2021","journal-title":"Biol Psychiatry"},{"key":"2025101813533871000_11.11.e054160.70","doi-asserted-by":"publisher","DOI":"10.1016\/S1364-6613(98)01240-6"},{"key":"2025101813533871000_11.11.e054160.71","doi-asserted-by":"crossref","unstructured":"Chan SK , Chan HY , Honer WG . Predictors of treatment-resistant and Clozapine-Resistant schizophrenia: a 12-year follow-up study of First-Episode Schizophrenia-Spectrum disorders. Schizophrenia Bulletin 2020.","DOI":"10.1093\/schbul\/sbaa145"},{"key":"2025101813533871000_11.11.e054160.72","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1176\/appi.ajp.2019.18091088","article-title":"Cognitive change in schizophrenia and other psychoses in the decade following the first episode","volume":"176","author":"Zanelli","year":"2019","journal-title":"Am J Psychiatry"},{"key":"2025101813533871000_11.11.e054160.73","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2013.00643","article-title":"Ten year neurocognitive trajectories in first-episode psychosis","volume":"7","author":"Barder","year":"2013","journal-title":"Front Hum Neurosci"},{"key":"2025101813533871000_11.11.e054160.74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-020-0102-z","article-title":"The clinical course of schizophrenia in women and men\u2014a nation-wide cohort study","volume":"6","author":"Sommer","year":"2020","journal-title":"NPJ schizophrenia"},{"key":"2025101813533871000_11.11.e054160.75","first-page":"1","article-title":"Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review","volume":"2012","author":"Ochoa","year":"2012","journal-title":"Schizophr Res Treatment"},{"key":"2025101813533871000_11.11.e054160.76","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.59","article-title":"Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology","volume":"7","author":"Bak","year":"2017","journal-title":"Transl Psychiatry"},{"key":"2025101813533871000_11.11.e054160.77","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1017\/S0033291718003781","article-title":"Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-na\u00efve schizophrenia patients","volume":"49","author":"Ebdrup","year":"2019","journal-title":"Psychol Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-054160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:53:54Z","timestamp":1760820834000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-054160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":77,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,25]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/bmjopen-2021-054160"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-054160","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}